L1CAM and neoplasm: Recently, Karnezis et al. correlated L1CAM and other immunohistochemical markers with ProMisE subgroups in a population-based cohort of EC and found high L1CAM expression to be highly associated with tumours showing mutation-type p53 expression and to identify poor prognosis tumours within MMR-D and p53 wt molecular subgroups.31 Stelloo et al. found similar results in a large, non-population-based cohort of EC patients (PORTEC).14